Shares of InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) shot up 0.2% on Monday . The stock traded as high as $4.97 and last traded at $4.66. 32,751 shares were traded during trading, an increase of 188% from the average session volume of 11,369 shares. The stock had previously closed at $4.65.
InMed Pharmaceuticals Stock Performance
The company has a 50 day moving average of $0.85 and a two-hundred day moving average of $0.47.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Further Reading
- Five stocks we like better than InMed Pharmaceuticals
- Consumer Discretionary Stocks Explained
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What is the Nikkei 225 index?
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
